On Monday, 1 March 2021 the Federal Health Minister, the Hon Greg Hunt MP, announced the listing of ozanimod (Zeposia®) for the treatment of relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).
Ozanimod, an oral treatment, was approved for treatment of relapsing forms of MS in Australia by the Therapeutic Goods Administration (TGA) in July 2020. At this stage in Australia, Ozanimod has not been approved for secondary progressive disease.
Ozanimod is now the 14th disease-modifying therapy for MS to be listed on Australia’s PBS and is a valuable addition to the repertoire of affordable medications available to all people living with MS.
As no two people experience MS in the same way, it is important to discuss any potential treatments with their neurologist.
For more information head to MSA’s website.